Adlai Nortye Ltd

Adlai Nortye’s CEO sells 10 ADS after a price dip— a modest move that could signal short‑term caution, but doesn’t alter the company’s biopharma pipeline or long‑term strategy.

Adlai Nortye insiders boost long‑term value: CEO Lu Yang acquires 16.99 m Class B shares and RSUs, signaling confidence as the biotech eyes upcoming clinical milestones.

Adlai Nortye insider filings reveal long‑term confidence amid explosive 680 % revenue growth, a pending closed‑trading window, and key clinical milestones that could drive future value.